Drug choice cuts lung transplant failure risk in half, study finds
A major clinical trial shows tacrolimus-based immunosuppression reduces chronic lung allograft dysfunction to 13% versus 39% with alternative treatments at three years. The finding could reshape transplant protocols and reduce costly graft failures—the leading cause of long-term death after lung transplantation.
Originaltitel: Phenotyping of chronic lung allograft dysfunction in the ScanCLAD study: a research letter
<title>Extract</title> Chronic lung allograft dysfunction (CLAD) remains the primary cause of long-term death or graft-failure after lung transplantation. The ScanCLAD trial demonstrated that tacrolimus-based immunosuppression significantly reduced CLAD incidence compared to ciclosporin (13% <italic>versus</italic> 39% at 3 years). However, CLAD phenotyping was not part of the original protocol. We report the first comprehensive phenotype analysis from a prospective randomized controlled trial in lung transplantation, employing a structured consensus process to classify CLAD phenotypes and assess their stability over time.